Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.

Leukemia - 1 Jan 2011

Song W, Tai Y-T, Tian Z, Hideshima T, Chauhan D, Nanjappa P, Exley M A, Anderson K C, Munshi N C

Abstract excerpt

LBH589 is a novel pan-histone deacetylase (HDAC) inhibitor that has potent antitumor activity in multiple myeloma and other hematological malignancies. However, its impact on the immune system has not been defined. We here evaluated the effects of LBH589 on human myeloid dendritic cells (DCs) at...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CD40 Antigens
Share to Dendritic Cells
Share to Histone Deacetylase Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hydroxamic Acids

Share to Indoles

Share to Myeloid Cells

Share to Natural Killer T-Cells

Share to NF-kappa B

Source

Open in PubMed Open full text

Identifiers

PMID: 21102427
DOI: 10.1038/leu.2010.244
PMCID: PMC3839585

Genes

TLR4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-21102427-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

HDAC inhibition by LBH589 affects the phenotype and function of human myeloid dendritic cells.PMID 21102427Read ↗

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunitySemantic proximity Read ↗

Advances of HDAC inhibitors in tumor therapy: potential applications through immune modulationSemantic proximity Read ↗

Targeting histone deacetylases for the treatment of cancer and inflammatory diseasesSemantic proximity Read ↗

Histone Deacetylase Inhibitors as Immunomodulators in Cancer TherapeuticsSemantic proximity Read ↗

Exploring the role of histone deacetylase and histone deacetylase inhibitors in the context of multiple myeloma: mechanisms, therapeutic implications, and future perspectivesSemantic proximity Read ↗

HDAC Inhibitors as Epigenetic Regulators of the Immune System: Impacts on Cancer Therapy and Inflammatory DiseasesSemantic proximity Read ↗

Immune modulation underpins the anti‐cancer activity of HDAC inhibitorsSemantic proximity Read ↗

Function of Histone Deacetylase Inhibitors in InflammationSemantic proximity Read ↗

How do tumor cells respond to HDAC inhibition?Semantic proximity Read ↗

HDAC1-3 inhibition reduces CCR2 expression and immunosuppressive function of myeloid-derived suppressor cellsSemantic proximity Read ↗

Regulation of Chemokines and Cytokines by Histone Deacetylases and an Update on Histone Decetylase Inhibitors in Human DiseasesSemantic proximity Read ↗

HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.